The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL

BJU International

Volumn 85, Issue 6, 2000, Pages 708-714

  Okegawa, T ^a,b   Kinjo, M ^a   Watanabe, K ^a   Noda, H ^a   Kato, M ^a   Miyata, A ^a   Murata, A ^a   Yoshii, M ^a   Nutahara, K ^a   Higashihara, E ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Complexed PSA; Free to complexed PSA ratio; Prostate; Prostate volume; Transition zone

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 0034070024     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00602.x     Document Type: Article

References (29)

1. 1 Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
2. 2 Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection and prostate cancer. J Urol 1994; 151: 1283-90
3. 3 Benson MC, Whang IS, Olsson CA et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21
4. 4 Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a mean of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6
5. 5 Oesterling JE, Jacobsen LA, Chute CG et al. Serum prostate specific antigen in a community-based population of healthy man: establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
6. 6 Kalish J, Cooner WH, Graham SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume, (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994; 43: 601-6
7. 7 Catalona WJ, Smith DS, Wolfert RL. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
8. 8 Zlotta AR, Djavan B, Marberger M et al. Prostate specific-antigen density of transition zone a new effective parameter for prostate cancer prediction. J Urol 1997; 157: 1315-21
9. 9 Stenman UH, Leinonen J, Alfthan H et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
10. 10 Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
11. 11 Lilja H, Cockett ATK, Abrahamsson P-A. Prostate specific antigen predominantly forms a complex with α1-antichymotrypsin in blood. Cancer 1992; 70: 230-4
12. 12 Pettersson K, Pilronen T, Seppala M et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem 1995; 41: 1480-8
13. 13 Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44: 1216-23
14. 14 Terris MK, Stamy TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984-7
15. 15 Zhou Z, Ng PC, Very DL et al. Technicon immuno 1 PSA assay measures both free and alpha-1-antichymotrypsin-complexed prostate specific antigen on an equimolar basis. J Clin Lab Anal 1996; 10: 155-9
16. 16 Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha-1-antichymotrypsin. Urol Clin N Amer 1993; 20: 681-6
17. 17 Hanley JA, McNeil BJ. Determination of prostate volume by a receiver operating characteristics (ROC) curve. Radiology 1982; 143: 29-36
18. 18 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 1983; 148: 839-43
19. 19 Brawer MK, Meyer GE, Letran JL et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8
20. 20 Brawer MK, Baukson DO, Partin AW et al. Complexed PSA. results of a multicenter biopsy experience. J Urol 1999; 161: 208(A796)
21. 21 Sokoll LJ, Bruzek DJ, Cox JL et al. Is complexed PSA alone clinically useful? J Urol 1998; 159: 234(A895)
22. 22 Higashihara E, Nutahara K, Kojima M et al. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol 1996; 156: 1964-8
23. 23 Djavan B, Zlotta AR, Byttebier G et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998; 160: 411-9
24. 24 Kurita Y, Terada H, Suzuki K et al. Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (γ-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA level. Br J Urol 1998; 82: 224-30
25. 25 Wang TJ, Linton HJ, Payne J et al. Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT. J Urol 1997; 157: 147(A575)
26. 26 Chan DW, Kelley CA, Partin AW. PSA-ACT immunoassay. Problems and solutions. Clin Chem 1996; 42: S255(A664)
27. 27 Zhang P, Wu JT. Development of an immunoassay specific for the PSA-ACT complex in serum without interference of non-specific adsorption. Clin Chem 1997; 43: S236(A604)
28. 28 Bjork T, Piironen T, Pettersson K et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996; 48: 882-8
29. 29 Jung K, Brux B, Lein M et al. Determination of antigen-alpha 1 -antichymotrypsin complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology 1999; 53: 1160-8